Latest & greatest articles for cannabis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cannabis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cannabis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cannabis

1. Pharmacotherapy for the Treatment of Cannabis Use Disorder

Pharmacotherapy for the Treatment of Cannabis Use Disorder Management Briefs eBrief-no151 -- Pharmacotherapy for the Treatment of Cannabis Use Disorder Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no151 -- Pharmacotherapy for the Treatment of Cannabis Use Disorder Health Services Research & Development Management eBrief no. 151 » Issue 151 April 2019 The report is a product (...) of the VA/HSR&D Evidence Synthesis Program. Pharmacotherapy for the Treatment of Cannabis Use Disorder: A Systematic Review Social, medical, and legal acceptance of cannabis has grown dramatically over the last 15 years, and cannabis use — for medical and recreational purposes — also has increased. From 2002 to 2012, the prevalence of daily cannabis use in the United States increased from 1.3 to 2.1%. Along with an increase in the acceptance and use of cannabis, the potency of cannabis available

2019 Veterans Affairs - R&D

2. Clearing the Smoke on Cannabis: Regular Use and Cognitive Functioning

Clearing the Smoke on Cannabis: Regular Use and Cognitive Functioning Key Points • Regular use refers to weekly or more frequent cannabis use over a period of months to years. Regular cannabis use is associated with mild cognitive difficulties, which are typically not apparent following about one month of abstinence. Heavy (daily) and long-term cannabis use is related to more noticeable cognitive impairment. • Cannabis use beginning prior to the age of 16 or 17 is one of the strongest (...) predictors of cognitive impairment. However, it is unclear which comes first — whether cognitive impairment leads to early onset cannabis use or whether beginning cannabis use early in life causes a progressive decline in cognitive abilities. • Regular cannabis use is associated with altered brain structure and function. Once again, it is currently unclear whether chronic cannabis exposure directly leads to brain changes or whether differences in brain structure precede the onset of chronic cannabis use

2019 Canadian Centre on Substance Abuse

3. Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. (PubMed)

Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. Little is known about the relative harms of edible and inhalable cannabis products.To describe and compare adult emergency department (ED) visits related to edible and inhaled cannabis exposure.Chart review of ED visits between 1 January 2012 and 31 December 2016.A large urban academic hospital in Colorado.Adults with ED visits with a cannabis-related International Classification of Diseases, Ninth or 10th (...) Revision, Clinical Modification (ICD-9-CM or ICD-10-CM), code.Patient demographic characteristics, route of exposure, dose, symptoms, length of stay, disposition, discharge diagnoses, and attribution of visit to cannabis.There were 9973 visits with an ICD-9-CM or ICD-10-CM code for cannabis use. Of these, 2567 (25.7%) visits were at least partially attributable to cannabis, and 238 of those (9.3%) were related to edible cannabis. Visits attributable to inhaled cannabis were more likely

2019 Annals of Internal Medicine

4. Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase

Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Seizures may be reduced in some severe drug-resistant epilepsies by a cannabis derivative Discover Portal Discover Portal Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Published on 26 June 2018 doi: In people with some types of severe, drug-resistant epilepsy, adding cannabidiol to their treatment may reduce seizure (...) an alternative. There has been widespread interest from the public and the media in the medical use of cannabis and its active components (called cannabinoids). The medicinal grade cannabinoid studied in the main trials of this review do not have hallucinogenic effects. Laboratory and animal studies have suggested that cannabinoids might reduce epileptic seizures, and they have shown promise in some studies in people with severe epilepsy. However, there has been concern about the quality of these studies

2019 NIHR Dissemination Centre

5. Pharmacotherapies for cannabis dependence. (PubMed)

Pharmacotherapies for cannabis dependence. Globally, cannabis use is prevalent and widespread. There are currently no pharmacotherapies approved for treatment of cannabis use disorders.This is an update of a Cochrane Review first published in the Cochrane Library in Issue 12, 2014.To assess the effectiveness and safety of pharmacotherapies as compared with each other, placebo or no pharmacotherapy (supportive care) for reducing symptoms of cannabis withdrawal and promoting cessation (...) or reduction of cannabis use.We updated our searches of the following databases to March 2018: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO and Web of Science.Randomised controlled trials (RCTs) and quasi-RCTs involving the use of medications to treat cannabis withdrawal or to promote cessation or reduction of cannabis use, or both, in comparison with other medications, placebo or no medication (supportive care) in people diagnosed as cannabis dependent or who

Full Text available with Trip Pro

2019 Cochrane

6. The cardiovascular effects of recreational cannabis use

The cardiovascular effects of recreational cannabis use Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

7. Effectiveness of cannabis-based therapeutic interventions in treatment of cancer patients: a systematic review

Effectiveness of cannabis-based therapeutic interventions in treatment of cancer patients: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

8. Cannabis use in individuals with clinically high-risk (CHR) of psychosis: A comprehensive review

Cannabis use in individuals with clinically high-risk (CHR) of psychosis: A comprehensive review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

9. Cannabis use during opioid substitution treatment: a systematic review

Cannabis use during opioid substitution treatment: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

10. Cannabis use and nonuse in patients with first-episode psychosis: a systematic review and meta-analysis of studies comparing neurocognitive functioning

Cannabis use and nonuse in patients with first-episode psychosis: a systematic review and meta-analysis of studies comparing neurocognitive functioning Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

11. Cannabis in end-of-life care: a review and rationale of current evidence

Cannabis in end-of-life care: a review and rationale of current evidence Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

12. The effects of recreational cannabis use in people with diabetes: a rapid review

The effects of recreational cannabis use in people with diabetes: a rapid review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

13. Cannabis

Cannabis This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. © The Author(s) 2018. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. 1 Received: October 10, 2018; Accepted: October 17, 2018 Original Article Canadian Association (...) of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders Christopher N. Andrews MD, MSc 1 , Shane M. Devlin MD 1 , Bernard Le Foll MD, PhD 2,3,4,5 , Benedikt Fischer PhD 6 , Frances Tse MD, MPH 7 , Martin Storr MD 8 , Stephen E. Congly MD, MSc 1 1 Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; 2 T ranslational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Centre

2018 Canadian Association of Gastroenterology

14. Cannabis for the treatment of ulcerative colitis. (PubMed)

Cannabis for the treatment of ulcerative colitis. Cannabis and cannabinoids are often promoted as treatment for many illnesses and are widely used among patients with ulcerative colitis (UC). Few studies have evaluated the use of these agents in UC. Further, cannabis has potential for adverse events and the long-term consequences of cannabis and cannabinoid use in UC are unknown.To assess the efficacy and safety of cannabis and cannabinoids for the treatment of patients with UC.We searched (...) MEDLINE, Embase, WHO ICTRP, AMED, PsychINFO, the Cochrane IBD Group Specialized Register, CENTRAL, ClinicalTrials.Gov and the European Clinical Trials Register from inception to 2 January 2018. Conference abstracts and references were searched to identify additional studies.Randomized controlled trials (RCTs) comparing any form or dose of cannabis or its cannabinoid derivatives (natural or synthetic) to placebo or an active therapy for adults (> 18 years) with UC were included.Two authors

2018 Cochrane

15. Cannabis for the treatment of Crohn's disease. (PubMed)

Cannabis for the treatment of Crohn's disease. Crohn's disease (CD) is a chronic immune-mediated condition of transmural inflammation in the gastrointestinal tract, associated with significant morbidity and decreased quality of life. The endocannabinoid system provides a potential therapeutic target for cannabis and cannabinoids and animal models have shown benefit in decreasing inflammation. However, there is also evidence to suggest transient adverse events such as weakness, dizziness (...) and diarrhea, and an increased risk of surgery in people with CD who use cannabis.The objectives were to assess the efficacy and safety of cannabis and cannabinoids for induction and maintenance of remission in people with CD.We searched MEDLINE, Embase, AMED, PsychINFO, the Cochrane IBD Group Specialized Register, CENTRAL, ClinicalTrials.Gov, and the European Clinical Trials Register up to 17 October 2018. We searched conference abstracts, references and we also contacted researchers in this field

2018 Cochrane

16. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies

Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies This review examines evidence for the effectiveness of cannabinoids in chronic noncancer pain (CNCP) and addresses gaps in the literature by: considering differences in outcomes based on cannabinoid type and specific CNCP condition; including all study designs; and following IMMPACT guidelines. MEDLINE, Embase, PsycINFO

2018 EvidenceUpdates

17. Growing at Home: Health and Safety Concerns for Personal Cannabis Cultivation

Growing at Home: Health and Safety Concerns for Personal Cannabis Cultivation GROWING AT HOME: HEALTH AND SAFETY CONCERNS FOR PERSONAL CANNABIS CULTIVATION PURPOSE Personal cultivation as described by the proposed Cannabis Act (2017) 1 will permit adults to cultivate up to four canna- bis plants per household. This provision is intended to both promote equity by facilitating access to legal cannabis, par- ticularly when retail outlets are difficult to access, and to undercut the black market (...) . However, indoor cultivation and processing of cannabis may also introduce or exacerbate certain environmental health risks in the home. This document identifies health and safety concerns that may be relevant to personal cultivation after legalization – that is, legal home growing and the associated health risks. Although this information may be of relevance to the public at large, the evidence presented here has been synthesized and organized for policy- and decision-makers, environmen- tal

2018 National Collaborating Centre for Environmental Health

18. Clearing the Smoke on Cannabis: Maternal Cannabis Use during Pregnancy ? An Update

Clearing the Smoke on Cannabis: Maternal Cannabis Use during Pregnancy ? An Update Key Points • Cannabis is the illicit drug most commonly used during pregnancy. • Constituents of cannabis can pass into breast milk during lactation and are absorbed and metabolized by the infant. • Frequent cannabis use during pregnancy is associated with low birth weight and is part of a cluster of risk-factors correlated with other adverse birth outcomes. • Prenatal and early exposure to cannabis can alter (...) neurodevelopment leading to adverse effects on cognition and academic achievement. • There are also effects on behaviour in children and young adults, including attention deficits, increased hyperactivity and impulsivity, and increased likelihood of substance use. • Information on the effects of cannabis use during pregnancy is essential to help healthcare providers advise patients about the impact of cannabis use and improve the health and well-being of patients and their children. Background After alcohol

2018 Canadian Centre on Substance Abuse

19. Cannabis

Cannabis Top results for cannabis - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for cannabis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

20. Cannabis

Cannabis www.ccsa.ca • www.ccdus.ca June 2018 Canadian Drug Summary Canadian Centre on Substance Use and Addiction • Centre canadien sur les dépendances et l’usage de substances Page 1 Cannabis Introduction Cannabis, more commonly called marijuana, is a tobacco-like greenish or brownish material consisting of the dried flowers, fruiting tops and leaves of the cannabis plant, Cannabis sativa. Hashish or cannabis resin is the dried brown or black resinous secretion of the flowering tops (...) of the cannabis plant and can be further processed to produce hash oil, wax or shatter. There is preliminary evidence of higher risks of resins due to the higher concentrations of THC. Cannabis is usually smoked as a cigarette (“joint”) or smoked as resins in a pipe or bong, also known as “dabbing.” 1 Vaporizers are also used to reduce the toxins inhaled from cannabis smoke. Some individuals who use cannabis slice open and hollow out cigars and replace the tobacco with marijuana (called “blunts”). In some

2018 Canadian Centre on Substance Abuse